ArticleMolecular pathology : MP2002
Expression of proteinases and inhibitors in human breast cancer progression and survival.
Article in Molecular pathology : MP, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 85 citations in OpenAlex.
- Matrix Metalloproteinase Gene Polymorphisms Are Associated with Breast Cancer in the Caucasian Women of Russia.International journal of molecular sciences · 2022Article
- The Modifying Effect of Obesity on the Association of Matrix Metalloproteinase Gene Polymorphisms with Breast Cancer Risk.Biomedicines · 2022Article
- MicroRNA‑212 facilitates the motility and invasiveness of esophageal squamous carcinoma cells.Molecular medicine reports · 2019Article
- Association between Expression of Tissue Inhibitors of Metalloproteinases-1, Matrix Metalloproteinase-2, and Matrix Metalloproteinase-9 Genes and Axillary Lymph Nodes Metastasis in Patients with Breast Cancer.International journal of preventive medicine · 2019Article
- Loss of Kaiso expression in breast cancer cells prevents intra-vascular invasion in the lung and secondary metastasis.PloS one · 2017Article
- Role of MMP-2 (-1306 C/T) Polymorphism in Pituitary Adenoma.Scientifica · 2016Article
- MMP-2 -1306C>T polymorphism in breast cancer: a case-control study in a South European population.Molecular biology reports · 2013Article
- Plasma levels of matrix metalloproteinases 2 and 9 correlate with histological grade in breast cancer patients.Oncology letters · 2013Article
- Microenvironmental control of the breast cancer cell cycle.Anatomical record (Hoboken, N.J. : 2007) · 2012Review
- Infrared (810-nm) low-level laser therapy on rat experimental knee inflammation.Lasers in medical science · 2012Article
- Article
- Type IIB procollagen NH(2)-propeptide induces death of tumor cells via interaction with integrins alpha(V)beta(3) and alpha(V)beta(5).The Journal of biological chemistry · 2010Article
- Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer.Journal of cancer research and clinical oncology · 2010Article
- Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma.Oncology letters · 2010Article
- Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells.Journal of signal transduction · 2010Article
- Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009Article
- Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production.American journal of respiratory cell and molecular biology · 2008Article
- Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse.British journal of cancer · 2007Article
- Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity.Cancer cell international · 2005Article
- Comparative study of matrix metalloproteinase expression between African American and Caucasian Women.Journal of carcinogenesis · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe expression of proteinases and their inhibitors determines the extracellular matrix (ECM) turnover in normal and pathological processes. In cancer, proteolysis is abnormally regulated, favouring ECM degradation, which aids tumour invasion and metastasis. Previous studies have determined the expression of proteinases and inhibitors in breast cancer using a variety of techniques, including immunohistochemistry; however, most have looked at the expression of individual proteinases and/or inhibitors. Therefore, the aim of the current study was to determine the simultaneous cellular expression of matrix metalloproteinases (MMPs), plasminogen activators (PAs), and tissue inhibitors of metalloproteinases (TIMPs) in patients with breast cancer and correlate this with clinical pathological staging and survival.
methodsImmunohistochemistry was used to determine the expression of proteinases (MMP-1, MMP-2, MMP-3, MMP-9, urokinase-type PA, and tissue-type PA) and inhibitors (TIMP-1 and TIMP-2) in 44 patients with breast cancer.
resultsThe expression of all the factors studied was stronger or equivalent in tumour cells than in fibroblasts or inflammatory cells within the tumour section. Both positive and negative trends have emerged in the correlation between the cellular expression of proteinases and inhibitors and breast tumour pathology (tumour grade, lymphovascular invasion, and Nottingham prognostic index).
conclusionsThe interactions between proteinases and their inhibitors in breast cancer progression are complex. Although there are differences in the expression of these factors that relate to differences in breast cancer pathology, there are no outstanding individual factors that consistently correlate with prognosis. Therefore, different factors are probably important at different stages of the process, and the balance in the relative concentrations of proteinases and inhibitors probably determines ECM degradation in breast tumour invasion and metastasis in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.